| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia (NCT07153796) | M.D. Anderson Cancer Center | 2026-01-30 |
| Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers (NCT07164456) | M.D. Anderson Cancer Center | 2026-01-13 |
| Decoupling Immunotherapy Toxicity and Cancer Response (NCT07382752) | M.D. Anderson Cancer Center | 2026-01-09 |
| A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE) (NCT07298096) | M.D. Anderson Cancer Center | 2026-01-08 |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) (NCT07128381) | M.D. Anderson Cancer Center | 2026-01-02 |
| Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM) (NCT07053033) | M.D. Anderson Cancer Center | 2026-01-01 |
| A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in Patients With Advanced Cancer: a Pilot Clinical Trial (NCT07246954) | M.D. Anderson Cancer Center | 2025-12-22 |
| Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK) (NCT07101432) | M.D. Anderson Cancer Center | 2025-12-19 |
| CARE-BI:a Pilot Study to Improve Patient Comfort and Reduce Psychological Distress During IA Removal (NCT07335302) | M.D. Anderson Cancer Center | 2025-12-18 |
| Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study (NCT06744816) | M.D. Anderson Cancer Center | 2025-12-11 |
| A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (NCT07193550) | M.D. Anderson Cancer Center | 2025-12-05 |
| A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma (NCT07116486) | M.D. Anderson Cancer Center | 2025-12-02 |
| A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations (NCT07325253) | M.D. Anderson Cancer Center | 2025-11-18 |
| Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules (NCT07226804) | M.D. Anderson Cancer Center | 2025-11-14 |
| A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer (NCT07133425) | M.D. Anderson Cancer Center | 2025-11-06 |
| Chronic Loose Stools Following Right-sided Hemicolectomy for Colon Cancer and the Association With Bile Acid Malabsorption and Small Intestinal Bacterial Overgrowth Using a Novel Sampling Device (NCT06927011) | M.D. Anderson Cancer Center | 2025-10-31 |
| A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer (NCT07223567) | M.D. Anderson Cancer Center | 2025-10-27 |
| Mediterranean Diet Intervention Among Men at LBJ Hospital With Prostate Cancer (NCT06935097) | M.D. Anderson Cancer Center | 2025-10-24 |
| A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma (NCT07229417) | M.D. Anderson Cancer Center | 2025-10-22 |
| Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project (NCT06878144) | M.D. Anderson Cancer Center | 2025-10-20 |
| Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (NCT06817720) | M.D. Anderson Cancer Center | 2025-10-13 |
| The Impact of Surgeon-Interpreted Intraoperative Margin Assessment During Breast Conserving Surgery on Postoperative Treatment (NCT07140965) | M.D. Anderson Cancer Center | 2025-10-09 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial (NCT07407920) | M.D. Anderson Cancer Center | 2025-10-09 |
| Universal Biospecimen Collection Protocol for Extra Material From Clinical Pulmonary Procedures (NCT07218939) | M.D. Anderson Cancer Center | 2025-10-08 |
| A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses (NCT06851507) | M.D. Anderson Cancer Center | 2025-10-06 |
| Evaluation of Meaning-centered Group Psychotherapy in Integrative Medicine (NCT07147205) | M.D. Anderson Cancer Center | 2025-10-03 |
| Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS (NCT07076186) | M.D. Anderson Cancer Center | 2025-10-02 |
| Quality of Life in Breast Cancer Survivors Who Were Pregnant During Their Cancer Treatment (NCT07191496) | M.D. Anderson Cancer Center | 2025-10-01 |
| T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. (NCT06474676) | M.D. Anderson Cancer Center | 2025-09-29 |
| Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes (NCT07220096) | M.D. Anderson Cancer Center | 2025-09-25 |
| A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) (NCT06561074) | M.D. Anderson Cancer Center | 2025-09-25 |
| Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma (NCT07072234) | M.D. Anderson Cancer Center | 2025-09-25 |
| Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT05668949) | M.D. Anderson Cancer Center | 2025-09-23 |
| Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-care (NCT06850402) | M.D. Anderson Cancer Center | 2025-09-22 |
| Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) (NCT07011654) | M.D. Anderson Cancer Center | 2025-09-19 |
| Feasibility Testing of a Dyadic Exercise Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers (NCT07234799) | M.D. Anderson Cancer Center | 2025-09-18 |
| Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) (NCT06586892) | M.D. Anderson Cancer Center | 2025-09-15 |
| Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations (NCT07032727) | M.D. Anderson Cancer Center | 2025-09-12 |
| SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma (NCT07049848) | M.D. Anderson Cancer Center | 2025-09-11 |
| Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention (NCT07186556) | M.D. Anderson Cancer Center | 2025-09-09 |
| A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer (NCT07137390) | M.D. Anderson Cancer Center | 2025-09-03 |
| A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies (NCT06930651) | M.D. Anderson Cancer Center | 2025-09-03 |
| Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation (NCT07140770) | M.D. Anderson Cancer Center | 2025-09-02 |
| Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas (NCT07215611) | M.D. Anderson Cancer Center | 2025-09-02 |
| Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients With Advanced Cancer (NCT05904782) | M.D. Anderson Cancer Center | 2025-08-29 |
| Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI) (NCT06885203) | M.D. Anderson Cancer Center | 2025-08-27 |
| Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) (NCT07053059) | M.D. Anderson Cancer Center | 2025-08-26 |
| Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer (NCT07076485) | M.D. Anderson Cancer Center | 2025-08-19 |
| A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis (NCT06906900) | M.D. Anderson Cancer Center | 2025-08-18 |
| Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers (NCT07140757) | M.D. Anderson Cancer Center | 2025-08-18 |
| Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer (NCT07142005) | M.D. Anderson Cancer Center | 2025-08-15 |
| Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer (NCT07011550) | M.D. Anderson Cancer Center | 2025-08-15 |
| A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) (NCT06959537) | M.D. Anderson Cancer Center | 2025-08-13 |
| Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose) (NCT06912763) | M.D. Anderson Cancer Center | 2025-08-08 |
| 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia (NCT07025512) | M.D. Anderson Cancer Center | 2025-08-03 |
| Opiophobia in Adults With Advanced Cancer (NCT07093567) | M.D. Anderson Cancer Center | 2025-08-01 |
| A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias (NCT06474663) | M.D. Anderson Cancer Center | 2025-07-31 |
| Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer (NCT06959550) | M.D. Anderson Cancer Center | 2025-07-28 |
| STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1 (NCT07038915) | M.D. Anderson Cancer Center | 2025-07-28 |
| Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery (NCT06959511) | M.D. Anderson Cancer Center | 2025-07-22 |
| A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease (NCT06973668) | M.D. Anderson Cancer Center | 2025-07-22 |
| Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer (NCT07105033) | M.D. Anderson Cancer Center | 2025-07-21 |
| EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial (NCT06897488) | M.D. Anderson Cancer Center | 2025-07-17 |
| Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). (NCT06967610) | M.D. Anderson Cancer Center | 2025-07-15 |
| Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study. (NCT06616649) | M.D. Anderson Cancer Center | 2025-07-14 |
| Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy (NCT07009886) | M.D. Anderson Cancer Center | 2025-07-10 |
| Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia (NCT06769490) | M.D. Anderson Cancer Center | 2025-07-10 |
| A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC (NCT06826768) | M.D. Anderson Cancer Center | 2025-07-09 |
| Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study (NCT06759701) | M.D. Anderson Cancer Center | 2025-07-02 |
| Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT06940518) | M.D. Anderson Cancer Center | 2025-07-02 |
| Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors (NCT06651593) | M.D. Anderson Cancer Center | 2025-07-02 |
| Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck (NCT05845307) | M.D. Anderson Cancer Center | 2025-06-20 |
| A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma (NCT06670105) | M.D. Anderson Cancer Center | 2025-06-06 |
| Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer (NCT06545604) | M.D. Anderson Cancer Center | 2025-06-06 |
| Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases (NCT07011849) | M.D. Anderson Cancer Center | 2025-06-04 |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer (NCT05873192) | M.D. Anderson Cancer Center | 2025-06-03 |
| Dissemination and Implementation of DIGESTâ„¢ as an Evidence-based Measurement Tool for Dysphagia: A Randomized Implementation Trial (NCT07283653) | M.D. Anderson Cancer Center | 2025-06-01 |
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors (NCT06801041) | M.D. Anderson Cancer Center | 2025-05-23 |
| Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery (NCT06919874) | M.D. Anderson Cancer Center | 2025-05-14 |
| Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study (NCT06811233) | M.D. Anderson Cancer Center | 2025-05-08 |
| Multi-center MRD Registry for Inflammatory Breast Cancer (NCT06966050) | M.D. Anderson Cancer Center | 2025-05-05 |
| Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention (NCT07010315) | M.D. Anderson Cancer Center | 2025-05-01 |
| Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC (NCT06762808) | M.D. Anderson Cancer Center | 2025-05-01 |
| Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies (NCT06584955) | M.D. Anderson Cancer Center | 2025-05-01 |
| Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease (NCT06878131) | M.D. Anderson Cancer Center | 2025-04-18 |
| Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial (NCT06736600) | M.D. Anderson Cancer Center | 2025-04-18 |
| Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER) (NCT06760481) | M.D. Anderson Cancer Center | 2025-04-13 |
| A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary (NCT06754501) | M.D. Anderson Cancer Center | 2025-04-11 |
| Assessing User Satisfaction and Adherence to an Abbreviated Dietary Tracking App (MySnackTracker) Versus Full-intake Dietary Monitoring (NCT06919471) | M.D. Anderson Cancer Center | 2025-04-08 |
| Examining the Feasibility and Impact of a Clinic-based Food Farmacy and Digital Culinary Medicine Program Among Cancer Survivors Treated in a Safety Net Hospital (NCT06760754) | M.D. Anderson Cancer Center | 2025-03-31 |
| CPRIT: Patient Adherence to Lung Cancer Screening (NCT06872723) | M.D. Anderson Cancer Center | 2025-03-21 |
| Evaluating Occupational Stress in Surgeons and Musicians: A Multi-modal Pilot Study Using Wearable EEG, Biomarker Analysis and Validated Questionnaires (NCT06875882) | M.D. Anderson Cancer Center | 2025-03-17 |
| A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA (NCT06698822) | M.D. Anderson Cancer Center | 2025-03-10 |
| A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia (NCT06448013) | M.D. Anderson Cancer Center | 2025-03-07 |
| Supporting Informed Decision Making About Multi-cancer Early Detection Testing (NCT06870916) | M.D. Anderson Cancer Center | 2025-03-07 |
| Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors (NCT06563375) | M.D. Anderson Cancer Center | 2025-03-05 |
| A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (NCT06548230) | M.D. Anderson Cancer Center | 2025-03-05 |
| Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation (NCT06807606) | M.D. Anderson Cancer Center | 2025-03-03 |
| Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions (NCT06561087) | M.D. Anderson Cancer Center | 2025-02-27 |
| Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma (NCT04199026) | M.D. Anderson Cancer Center | 2025-02-25 |